A total of 11 patients were affected by the use of Armillarisin, produced by the Tē Tē Gābǐ Pharmaceutical Company (indicated for treating hepatitis), of which four have died and six others are in critical condition.
According to Professor Cao Zhi Liang, head of the Infectious Diseases Department at the Third Hospital of Sun Yat-sen University in Guangdong Province, during the days of April 29 and 30, hepatitis patients in the department suddenly exhibited common symptoms of severe kidney failure, prompting doctors to be vigilant.
Upon examination, it was found that the Armillarisin medication they were treated with was made from unidentified substances. Currently, the National Medical Products Administration of China has issued an emergency notice requiring the suspension of this medication nationwide.
UYÊN KIM
